UB Paderborn / Katalog / Suche / in CDI

In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens

Antimicrobial agents and chemotherapy, 2016-03, Vol.60 (3), p.1918-1923

2016

Volltextzugriff (PDF)

Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008–2009)

Clinical microbiology and infection, 2012-03, Vol.18 (3), p.253-259

2012

Volltextzugriff (PDF)

Determining incidence of extended spectrum β-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001–2002

International journal of antimicrobial agents, 2004-08, Vol.24 (2), p.119-124

2004

Volltextzugriff (PDF)

Trending Eight Years of In Vitro Activity of Ertapenem and Comparators Against Escherichia Coli from Intra-abdominal Infections in North America-SMART 2002-2009

Journal of chemotherapy (Florence), 2011-10, Vol.23 (5), p.266-272

2011

Volltextzugriff (PDF)

In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China

European journal of clinical microbiology & infectious diseases, 2016-12, Vol.35 (12), p.1933-1939

2016

Volltextzugriff (PDF)

In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007–2012

Diagnostic microbiology and infectious disease, 2014-05, Vol.79 (1), p.54-59

2014

Volltextzugriff (PDF)

A comparative in vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across europe, North America, and South America

Antimicrobial agents and chemotherapy, 2000-11, Vol.44 (11), p.3008-3011

2000

Volltextzugriff (PDF)

In vitro activity of gemifloxacin and contemporary oral antimicrobial agents against 27,247 Gram-positive and Gram-negative aerobic isolates: a global surveillance study

International journal of antimicrobial agents, 2004-02, Vol.23 (2), p.181-196

2004

Volltextzugriff (PDF)

Comparative in vitro potency of amoxycillin–clavulanic acid and four oral agents against recent North American clinical isolates from a global surveillance study

International journal of antimicrobial agents, 2003-05, Vol.21 (5), p.425-433

2003

Volltextzugriff (PDF)

Antimicrobial susceptibilities of clinical isolates of Haemophilus influenzae and Moraxella catarrhalis collected during 1999–2000 from 13 countries

Clinical microbiology and infection, 2001-12, Vol.7 (12), p.671-677

2001

Volltextzugriff (PDF)

Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study

Diagnostic microbiology and infectious disease, 2001-05, Vol.40 (1), p.51-57

2001

Volltextzugriff (PDF)

In vitro activity of tigecycline and comparators against carbapenem-resistant Enterobacteriaceae in Africa–Middle East countries: TEST 2007–2012

Journal of global antimicrobial resistance., 2014-09, Vol.2 (3), p.179-182

2014

Volltextzugriff (PDF)

Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries

European journal of clinical microbiology & infectious diseases, 2001-01, Vol.20 (1), p.55-60

2001

Volltextzugriff (PDF)

Comparative in vitro surveillance of amoxicillin-clavulanic acid and four oral comparators against 21,232 clinical isolates from Europe

European journal of clinical microbiology & infectious diseases, 2003-04, Vol.22 (4), p.261-267

2003

Volltextzugriff (PDF)

In-vitro activity of cefepime and other antimicrobials: Survey of European isolates

Journal of antimicrobial chemotherapy, 1993-11, Vol.32 (suppl-B), p.31-53

1993

Volltextzugriff (PDF)

In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002

Diagnostic microbiology and infectious disease, 2005-04, Vol.51 (4), p.291-295

2005

Volltextzugriff (PDF)

Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study

European journal of clinical microbiology & infectious diseases, 2001-11, Vol.20 (11), p.814-819

2001

Volltextzugriff (PDF)

A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae

Journal of antimicrobial chemotherapy, 1993-11, Vol.32 (suppl-B), p.13-19

1993

Volltextzugriff (PDF)

Antimicrobial susceptibility of extended-spectrum β-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial

Diagnostic microbiology and infectious disease, 2007-04, Vol.57 (4), p.423-428

2007

Volltextzugriff (PDF)

A Comparative In Vitro Surveillance Study of Gemifloxacin Activities against 2,632 Recent Streptococcus pneumoniaeIsolates from across Europe, North America, and South America

Antimicrobial Agents and Chemotherapy, 2000-11, Vol.44 (11), p.3008-3011

2000

Volltextzugriff (PDF)

Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum [beta]-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009)

Clinical microbiology and infection, 2012-03, Vol.18 (3), p.253

2012

Volltextzugriff (PDF)

In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)

Diagnostic microbiology and infectious disease, 2005-07, Vol.52 (3), p.215-227

2005

Volltextzugriff (PDF)

In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)

Diagnostic microbiology and infectious disease, 2005-07, Vol.52 (3), p.173-179

2005

Volltextzugriff (PDF)

Only percentage within species; neither incidence, nor prevalence: demographic information and representative surveillance data are urgently needed to estimate the burden of antimicrobial resistance

International journal of antimicrobial agents, 2004-12, Vol.24 (6), p.622-623

2004

Volltextzugriff (PDF)

In vitro activity of gemifloxacin and contemporary oral antimicrobial agents against 27247 Gram-positive and Gram-negative aerobic isolates: a global surveillance study

International journal of antimicrobial agents, 2004-02, Vol.23 (2), p.181-196

2004

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens

Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008–2009)

Determining incidence of extended spectrum β-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001–2002

Trending Eight Years of In Vitro Activity of Ertapenem and Comparators Against Escherichia Coli from Intra-abdominal Infections in North America-SMART 2002-2009

In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China

In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007–2012

A comparative in vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across europe, North America, and South America

In vitro activity of gemifloxacin and contemporary oral antimicrobial agents against 27,247 Gram-positive and Gram-negative aerobic isolates: a global surveillance study

Comparative in vitro potency of amoxycillin–clavulanic acid and four oral agents against recent North American clinical isolates from a global surveillance study

Antimicrobial susceptibilities of clinical isolates of Haemophilus influenzae and Moraxella catarrhalis collected during 1999–2000 from 13 countries

Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study

In vitro activity of tigecycline and comparators against carbapenem-resistant Enterobacteriaceae in Africa–Middle East countries: TEST 2007–2012

Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries

Comparative in vitro surveillance of amoxicillin-clavulanic acid and four oral comparators against 21,232 clinical isolates from Europe

In-vitro activity of cefepime and other antimicrobials: Survey of European isolates

In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002

Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study

A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae

Antimicrobial susceptibility of extended-spectrum β-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial

A Comparative In Vitro Surveillance Study of Gemifloxacin Activities against 2,632 Recent Streptococcus pneumoniaeIsolates from across Europe, North America, and South America

Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum [beta]-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009)

In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)

In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)

Only percentage within species; neither incidence, nor prevalence: demographic information and representative surveillance data are urgently needed to estimate the burden of antimicrobial resistance

In vitro activity of gemifloxacin and contemporary oral antimicrobial agents against 27247 Gram-positive and Gram-negative aerobic isolates: a global surveillance study

Suchergebnisse filtern